Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial.

European Heart Journal
Evan A SteinJennifer G Robinson

Abstract

Co-primary objectives were to evaluate dalcetrapib (JTT-705/RO4607381), which targets cholesteryl ester transfer protein (CETP), effects on high-density lipoprotein cholesterol (HDL-C) in participants with coronary heart disease or risk equivalents and to evaluate potential changes in mesenteric lymph nodes. Double-blind trial with participants randomized (2:1) to dalcetrapib 900 mg/day (higher than 600 mg phase III dose) or placebo, both with atorvastatin, for 24 weeks (n = 135; one without post-baseline efficacy data was excluded from intent-to-treat population); a subset continued for 24-week extension (n = 77). Lipid changes and safety parameters were assessed. Mesenteric lymph nodes were evaluated by magnetic resonance imaging. Dalcetrapib increased HDL-C (33.4%, Week 24; 33.8%, Week 48), decreased CETP activity (-53.5%, Week 24; -56.5%, Week 48), and increased apolipoprotein A-I (11.4%, Week 24; 16.4%, Week 48). Dalcetrapib showed no clinically relevant differences vs. placebo in adverse events, laboratory parameters including aldosterone, electrocardiograms, and vital signs including blood pressure (BP). Dalcetrapib had no measurable, clinically relevant effect on lymph node size. Dalcetrapib 900 mg administered for up t...Continue Reading

References

Jan 1, 1997·Arteriosclerosis, Thrombosis, and Vascular Biology·U GoldbourtJ H Medalie
Apr 13, 2001·JAMA : the Journal of the American Medical Association·S J RobinsUNKNOWN VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial
Apr 22, 2005·The American Journal of Cardiology·Jan Albert KuivenhovenJohn J P Kastelein
Mar 28, 2007·The New England Journal of Medicine·Steven E NissenUNKNOWN ILLUSTRATE Investigators
Mar 28, 2007·The New England Journal of Medicine·John J P KasteleinUNKNOWN RADIANCE 1 Investigators
Aug 21, 2007·JAMA : the Journal of the American Medical Association·Inder M SinghBenjamin J Ansell
Nov 7, 2007·The New England Journal of Medicine·Philip J BarterUNKNOWN ILLUMINATE Investigators
Jun 19, 2008·JAMA : the Journal of the American Medical Association·Alexander ThompsonJohn Danesh
Jul 7, 2009·The American Journal of Cardiology·Evan A SteinJohn J P Kastelein
Dec 5, 2009·American Heart Journal·Gregory G SchwartzUNKNOWN dal-OUTCOMES Committees and Investigators

❮ Previous
Next ❯

Citations

Jul 12, 2011·Current Atherosclerosis Reports·Kuang-Yuh ChyuPrediman K Shah
Nov 16, 2011·Current Atherosclerosis Reports·Gregory G Schwartz
Dec 18, 2012·Current Atherosclerosis Reports·Willibald Hochholzer, Robert P Giugliano
Sep 20, 2012·Current Cardiology Reports·Daniel B LarachDaniel J Rader
Mar 19, 2013·Biochemical Pharmacology·Kyriakos E KypreosIordanis Karagiannides
Jan 19, 2011·Nature Reviews. Cardiology·Emil M Degoma, Daniel J Rader
Nov 19, 2010·The New England Journal of Medicine·Christopher P CannonUNKNOWN Determining the Efficacy and Tolerability Investigators
Sep 11, 2012·The Journal of Biological Chemistry·Shenping LiuXiayang Qiu
May 12, 2011·Metabolic Syndrome and Related Disorders·Sridevi Devaraj, Ishwarlal Jialal
Jan 26, 2010·European Heart Journal·Arnold von Eckardstein
May 16, 2012·European Heart Journal·Thomas F LüscherWilliam Wijns
Feb 22, 2012·International Journal of Clinical Practice·A S WierzbickiA Viljoen
Oct 12, 2011·Lipids in Health and Disease·Santiago RedondoTeresa Tejerina
Oct 12, 2012·Drug Design, Development and Therapy·Alyse S Goldberg, Robert A Hegele
Aug 24, 2012·Journal of Geriatric Cardiology : JGC·Claudia F GravinaGiselle Hp Rodrigues
Jan 16, 2014·Annual Review of Medicine·Daniel J Rader, Emil M deGoma
Apr 30, 2014·Current Atherosclerosis Reports·Davide NotoMaurizio R Averna
Sep 13, 2011·Current Cardiology Reports·Peter P Toth
Mar 1, 2012·Current Cardiology Reports·Stephen J Nicholls
Feb 15, 2012·Expert Opinion on Investigational Drugs·Sheila A Doggrell
Oct 4, 2011·Expert Opinion on Investigational Drugs·Cesare R Sirtori
May 15, 2010·Expert Opinion on Investigational Drugs·Jennifer G Robinson
Aug 27, 2010·Expert Opinion on Investigational Drugs·Michael DerksMary Phelan
Jun 26, 2012·Expert Opinion on Investigational Drugs·Amanda J Hooper, John R Burnett
Oct 8, 2013·Clínica e investigación en arteriosclerosis : publicación oficial de la Sociedad Española de Arteriosclerosis·Pablo Corral, Laura Schreier
Sep 25, 2012·Drug Discovery Today·Brian J SchmidtCynthia J Musante
Apr 3, 2012·Pharmacology & Therapeutics·Tisha R Joy
Mar 7, 2012·The Medical Clinics of North America·Ragavendra R Baliga
Nov 18, 2011·Trends in Pharmacological Sciences·Philip Barter, Kerry-Anne Rye
Jul 22, 2010·Cardiovascular Therapeutics·Paul J W H KappelleRobin P F Dullaart
Dec 24, 2010·British Journal of Clinical Pharmacology·Michael DerksMary Phelan
May 12, 2015·The Journal of Clinical Investigation·John S MillarDaniel J Rader

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT00353522
NCT00400439
NCT00658515

Software Mentioned

SAS

Related Concepts

Related Feeds

Cardiology Journals

Discover the latest cardiology research in this collection of the top cardiology journals.